GT Biopharma Announces Dosing Of New Patient In GTB-3550 TriKE(TM) Phase I/II Clinical Trial May 27, 2020
GT Biopharma Announces Commencement of Retreatment of Patient Demonstrating Successful Clinical Benefit following GTB-3550 TriKE(TM) therapy March 31, 2020
UPDATE: GT Biopharma Announces Preliminary Results for GTB-3550 TriKE(TM) Phase I/II Clinical Trial for Treatment of Acute Myeloid Leukemia March 19, 2020
GT Biopharma Announces Preliminary Results for GTB-3550 TriKE(TM) Phase I/II Clinical Trial for Treatment of Acute Myeloid Leukemia March 19, 2020
GT Biopharma and Cytovance Biologics Announce Collaboration Agreement TriKE(TM) Therapeutic for Treatment of Coronavirus Infection March 10, 2020
GT Biopharma Announces Dosing First Patient In GTB-3550 TriKE(TM) Phase I/II Clinical Trial February 26, 2020
GT Biopharma Provides Update Concerning Trike(TM) Drug Development Programs and Other Strategic Initiatives January 21, 2020
GT Biopharma Announces Solid Tumor Targeting TriKe™ Kills Non-small Cell Lung Cancer (NSCLC) Tumor Cells October 22, 2019
